Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

Pfizer

Status: Completed

Conditions: Psoriatic Arthritis

Treatments: Drug: Enbrel

Study type: Observational

Funder types: Industry

Identifiers

NCT04428502

B1801418

Details and patient eligibility

About

This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.

Enrollment: 127 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed PsA patients.
• ≥18 years of age
• Have not received previous biological treatment

Exclusion criteria

• Previous use of other biological treatments.
• Etanercept use for less than 1 year duration.

Trial design

127 participants in 1 patient group

Patients with psoriatic arthritis

Description:

Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease

Treatment:

Drug: Enbrel